I-Mab is a holding company. Through its subsidiaries, Co. is primarily engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries. Co.'s drug pipeline includes: Felzartamab (TJ202), which is a monoclonal antibody directed against CD38; Eftansomatropin alfa (TJ101), which is a recombinant human growth hormone being developed as a therapy for growth hormone deficiency; Lemzoparlimab (TJC4), which is a CD47 monoclonal antibody discovered and developed internally by Co. for cancer immunotherapy; and Uliledlimab (TJD5), which is an inhibitory antibody against human CD73. The IMAB average annual return since 2020 is shown above.
The Average Annual Return on the IMAB average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IMAB average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IMAB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|